ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
127.159,91
0,98%
S&P 500
5.052,03
0,67%
US Dollar vs BRL
5,104
-1,77%
Bitcoin
59.034,68
1,37%
Brent Oil
83,75
0,25%
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immutep Ltd (IMMP)

  7. Immutep Ltd (IMMP) Notícias

IMMP Immutep Ltd

2,65
0,05 (1,92%)
Última atualização: 14:22:37
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
Immutep Ltd IMMP NASDAQ Recibo de Depósito
  Variação do Dia (p) Variação do Dia % Último Preço Hora
Upgrade Icon
0,05 1,92% 2,65 14:22:37
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
2,73 2,60 2,74 2,60
mais cotações »

Notícias Recentes

Data Hora Fonte Título
02/05/202409:00GLOBEPositive Initial Clinical Data Reported from Immutep’s Efti..
29/04/202409:00GLOBEImmutep Quarterly Activities Report Q3 FY24
24/04/202409:00GLOBEImmutep Announces Positive Preliminary Topline Results from..
18/04/202409:00GLOBEImmutep Appoints Leading Research Institute to Conduct..
17/04/202409:00GLOBEImmutep Receives Positive Feedback from the Spanish..
05/03/202410:00GLOBEImmutep Announces First Clinical Data from 90mg Dosing of..
30/01/202410:00GLOBEImmutep Quarterly Activities Report Q2 FY24
04/01/202410:00GLOBEFirst Patient Dosed in Trial Evaluating Efti and the..
21/12/202310:00GLOBEImmutep Receives Constructive Regulatory Feedback on..
07/12/202310:00GLOBEImmutep Receives A$2.6 million R&D Tax Incentive from French..
22/11/202310:00GLOBEImmutep Announces Site Expansion for INSIGHT-003 Phase I..
09/11/202310:00GLOBEImmutep Completes Enrollment in TACTI-003 Phase IIb Trial of..
06/11/202310:00GLOBEImmutep Announces Completion of the Safety Lead-In and..
03/11/202313:00GLOBEImmutep Announces New Biomarker Data from TACTI-002 Phase II..
02/11/202309:00GLOBEImmutep to Participate in November Investor Events
31/10/202309:00GLOBEImmutep Quarterly Activities Report Q1 FY24
25/10/202309:00GLOBEImmutep receives ~A$1.13 million R&D Tax Incentive
24/10/202309:00GLOBEImmutep Reports Promising Clinical Data from INSIGHT-003..
23/10/202309:00GLOBEImmutep’s Efti in Combination with KEYTRUDA® Generates..
16/10/202309:00GLOBEImmutep Announces Publication of Abstracts at ESMO Congress..
03/10/202309:00GLOBEImmutep Announces Abstract Accepted for Presentation at the..
21/09/202309:00GLOBECommercial Manufacturing of Eftilagimod Alpha at 2000L Scale..
05/09/202310:00GLOBEImmutep to Participate in September Investor Conferences
01/08/202309:00GLOBEImmutep Receives Positive Scientific Advice from European..
31/07/202309:00GLOBEImmutep to Present Overall Survival Data in 1st Line..
28/07/202309:00GLOBEFirst Patient Dosed in Chemotherapy-Free Triple Combination..
27/06/202309:00GLOBEImmutep Secures Third United States Patent for Eftilagimod..
20/06/202309:00GLOBEImmutep Granted United States Patent for IMP761, a..
07/06/202309:00GLOBEImmutep to Participate at the Jefferies Healthcare..
05/06/202309:00GLOBEImmutep Reports Final Positive Data in 2nd Line Head and..
02/06/202309:00GLOBEImmutep Successfully Completes Institutional Placement and..
29/05/202309:00GLOBEImmutep Selects Charles River Laboratories for IMP761’s GLP..
26/05/202309:00GLOBEImmutep Announces Publication of Abstracts for ASCO 2023..
25/05/202309:00GLOBEImmutep Doses First Patient in AIPAC-003 Phase II/III Trial..
24/05/202309:00GLOBEImmutep Announces Promising New Clinical Data from Triple..
17/05/202309:00GLOBEImmutep’s Efti in Combination with Pembrolizumab Achieves..
16/05/202309:00GLOBEImmutep Receives Positive Feedback from FDA on Late-Stage..
09/05/202309:00GLOBEImmutep to Participate in the JMP Securities Life Sciences..

Seu Histórico Recente

NASDAQ
IMMP
Immutep
Delayed Upgrade Clock
ADVFN Logo

Brasil
Empresa
Negócios
Popular
Obter o aplicativo

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados